Abstract: The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

Abstract: A non-aqueous patch preparation may include a drug solution in which a drug is dissolved in an organic solvent, a lipophilic mass base, and anhydrous silicic acid powders that are insoluble both in the organic solvent and in the lipophilic mass base. The organic solvent is selected from the group consisting of propylene glycol, 1,3-butanediol, polyethylene glycol, and propylene carbonate. The lipophilic mass base comprises an elastomer, a tackifier, and a softening agent wherein the elastomer is styrene-isoprene-styrene copolymer (SIS). The patch preparation has 2% to 10% by weight of the anhydrous silicic acid powders.

Abstract: The present invention provides an adjuvant composition which is excellent in safety and usability as well as can effectively enhance the immunogenicity of an antigen, and a vaccine composition using the adjuvant composition.

Abstract: The present invention provides a composition comprising an ionic liquid and a poorly absorbable drug, wherein the ionic liquid is prepared from an anion and a cation, the anion is an organic acid having 3 to 7 carbon atoms, and the cation is selected from the group consisting of arginine, meglumine, trometamol and diethanolamine, which remarkably improves the absorbability of the poorly absorbable drug.

Abstract: The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

Abstract: The present invention is to provide a combined preparation comprising a first preparation for transdermal administration comprising an antigenic peptide and an aliphatic carboxylic acid-based ionic liquid, and a second preparation for transdermal administration comprising an adjuvant and an aliphatic carboxylic acid-based ionic liquid, enhances the skin permeability of an antigenic peptide and an adjuvant and thus effectively enhances the effect of activating the immune response with the antigenic peptide by the use of the adjuvant.

Abstract: The present invention provides a microneedle array having microneedles coated with a composition comprising a poorly water-soluble or water-insoluble particle with a mean particle size of 1 ?m or less, 2% to 20% by weight of a binding agent and 60% by weight or more of water in which the poorly water-soluble or water-insoluble particle is loaded on the microneedles in equal amounts that shows good puncturability.

Abstract: A microneedle patch applicator housing, being formed from a single sheet or film having a top surface and an undersurface, the housing including a flat peripheral base part and a raised part surround by the peripheral base part and bulging vertically, with respect to the peripheral base part, from the undersurface toward the top surface, an undersurface portion of the raised part forming a surface supporting a microneedle patch, the raised part including a plurality of concavely bent parts, and the concavely bent parts each having a concave bottom toward a direction away from a center portion of the raised part.

Abstract: The present invention aims to provide a transdermal formulation in which apomorphine or a salt thereof is dissolved at a high concentration, so that a sufficient amount of apomorphine for treatment can be absorbed in a short time, and can be administered continuously. The present invention can include, for example, a transdermal formulation, comprising apomorphine or a salt thereof, a polyhydric alcohol with a carbon number of 6 or less and/or a low molecular weight polyethylene glycol, and propylene carbonate. According to the present invention, it is possible to prepare a solution containing apomorphine in a high concentration, and to allow a sufficient amount of apomorphine to be absorbed into the body through the skin in a short time and administered continuously.

Abstract: The present invention provides a novel siRNA specifically inhibiting the expression of IL-23 and a pharmaceutical composition comprising the siRNA, specifically a double stranded RNA comprising a sense strand and an antisense strand wherein each strand has 19 to 30 nucleotides and comprises the base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof and a pharmaceutical composition comprising the double stranded RNA.

Abstract: Disclosed is a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. This transdermal absorptive liquid formulation has a mode of particle diameter at around 100 nm, and an average particle size of 50 to 500 nm. This transdermal absorptive liquid formulation makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.

Abstract: The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

Abstract: An object of the present invention is to provide a method for the treatment of a patient suffering from spasticity comprising administering to said patient a modified release dosage form comprising tizanidine or a pharmaceutically acceptable salt thereof. The present invention relates to a method of administering a transdermal patch preparation comprising tizanidine or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the transdermal patch preparation releases about 4 mg to about 36 mg of tizanidine or a pharmaceutically acceptable salt thereof for at least about 24 hours.

Abstract: A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20° C.

Abstract: The present disclosure, for example, can include a laminated type patch A, comprising a release layer 1, a drug layer 2, a drug support layer 3 having elasticity, an adhesive layer 4, and an adhesive support layer 5 laminated in this order, wherein the outer edges of the release layer, the adhesive layer, and the adhesive support layer are all outside the outer edges of both the drug layer and the drug support layer; wherein the portion surrounded by the outer edges of the drug layer and the drug support layer, and the inner sides of the release layer and the adhesive layer has a space; and wherein the cross-sectional area of the space is 0.3 mm2 or more, at least when cut along the longitudinal centerline and the transverse centerline on the plane surfaces of the drug layer and the drug support layer.

Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

Abstract: Provided are a method of applying a microneedle array, and a patch or an assistant tool used therefor. When skin is to be stretched and punctured with microneedles, the microneedle array can be prevented from detaching from the skin by providing adhesive layers, with the microneedle array therebetween, in a direction different from the direction in which the skin is stretched. Additionally, the application method can be appropriately implemented by producing a patch or an assistant tool having a rigid flat plate. As a result, the microneedle array can be punctured more accurately with less stress.

Abstract: The present invention provides an external preparation composition comprising lactic acid salt of lidocaine consisting of lidocaine and a lactic acid ingredient and diclofenac or a salt thereof wherein the lactic acid ingredient is lactic acid and an alkali metal salt or alkaline earth metal salt of lactic acid, and an external preparation which exhibits higher transdermal absorbability of both lidocaine and diclofenac and the skin permeability suitable for clinical use, and enhances the storage stability and safety of the preparation to allow the long-term storage.

Abstract: The present invention provides a composition for external application comprising baclofen or a salt thereof, specifically baclofen hydrochloride with high transdermal absorbability and stability, and a method of stabilizing a preparation comprising baclofen or a salt thereof.

Abstract: A microneedle patch applicator housing, being formed from a single sheet or film having a top surface and an undersurface, the housing including a flat peripheral base part and a raised part surround by the peripheral base part and bulging vertically, with respect to the peripheral base part, from the undersurface toward the top surface, an undersurface portion of the raised part forming a surface supporting a microneedle patch, the raised part including a plurality of concavely bent parts, and the concavely bent parts each having a concave bottom toward a direction away from a center portion of the raised part.